Home > In process > Reduced Hospital Incidence of Autoimmune Encephalitis During the COVID-19 Pandemic. > print

001     285252
005     20260217094354.0
024 7 _ |a 10.1212/NXI.0000000000200555
|2 doi
024 7 _ |a pmid:41687038
|2 pmid
037 _ _ |a DZNE-2026-00194
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Wickel, Jonathan
|0 0000-0002-5854-3759
|b 0
245 _ _ |a Reduced Hospital Incidence of Autoimmune Encephalitis During the COVID-19 Pandemic.
260 _ _ |a Philadelphia, Pa.
|c 2026
|b Wolters Kluwer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1771317707_24909
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The aim of this study was to analyze changes in hospital incidence cases and disease severity of autoantibody-associated autoimmune encephalitis (AE) during the COVID-19 pandemic compared with the prepandemic period.A retrospective multicenter study analyzed data from 24 centers within the German Network for Research on Autoimmune Encephalitis (GENERATE). Patients with a new diagnosis of definite antibody-positive autoimmune encephalitis from 2017 to 2022 were included and divided into prepandemic (2017-2019) and pandemic (2020-2022) periods.Among 392 patients, 227 were diagnosed before and 165 during the pandemic (mean 9.5 vs 6.9 per site, p = 0.04). A reduction was observed in cases with antibodies to neuronal surface antigens (174 vs 122 cases; mean 7.3 vs 5.1 per site, p = 0.02), while cases with antibodies against intracellular antigens remained stable (p = 0.40). No differences were observed in disease severity, age, or sex distribution between periods.This study provides clinical data on antibody-positive AE before and during the COVID-19 pandemic. The findings do not support the hypothesis that SARS-CoV-2 infection triggers autoantibody-associated AE or increases disease severity.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Autoantibodies
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a COVID-19: epidemiology
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Retrospective Studies
|2 MeSH
650 _ 2 |a Incidence
|2 MeSH
650 _ 2 |a Encephalitis: epidemiology
|2 MeSH
650 _ 2 |a Encephalitis: immunology
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Germany: epidemiology
|2 MeSH
650 _ 2 |a Hashimoto Disease: epidemiology
|2 MeSH
650 _ 2 |a Hashimoto Disease: immunology
|2 MeSH
650 _ 2 |a Autoantibodies: blood
|2 MeSH
650 _ 2 |a Severity of Illness Index
|2 MeSH
650 _ 2 |a Young Adult
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
650 _ 2 |a Hospitalization: statistics & numerical data
|2 MeSH
700 1 _ |a Chung, Ha-Yeun
|b 1
700 1 _ |a Konen, Franz Felix
|0 0000-0002-8609-5674
|b 2
700 1 _ |a Rössling, Rosa
|0 P:(DE-2719)9001490
|b 3
700 1 _ |a Bertolini, Annikki
|0 0000-0003-4196-022X
|b 4
700 1 _ |a Kraft, Andrea
|0 0009-0001-3748-1798
|b 5
700 1 _ |a Siebenbrodt, Kai
|0 0000-0003-3827-4245
|b 6
700 1 _ |a Bittner, Stefan
|0 0000-0003-2179-3655
|b 7
700 1 _ |a Juranek, Aleksandra
|b 8
700 1 _ |a Brokbals, Mosche
|b 9
700 1 _ |a Räuber, Saskia
|0 0000-0001-8901-5572
|b 10
700 1 _ |a Klausewitz, Jaqueline
|0 0009-0009-9880-1191
|b 11
700 1 _ |a Pfeffer, Lena K
|0 0000-0003-3057-6492
|b 12
700 1 _ |a Scherag, André
|b 13
700 1 _ |a Menge, Til
|b 14
700 1 _ |a Finke, Alexander
|b 15
700 1 _ |a Doppler, Kathrin
|0 0000-0003-2883-0009
|b 16
700 1 _ |a Urbanek, Christian
|b 17
700 1 _ |a Bien, Christian G
|0 0000-0003-2225-8654
|b 18
700 1 _ |a Seifert-Held, Thomas
|0 0000-0001-8121-3662
|b 19
700 1 _ |a Hoffmann, Frank
|0 0000-0002-6242-6010
|b 20
700 1 _ |a Wandinger, Klaus-Peter
|0 0000-0002-5483-4276
|b 21
700 1 _ |a Tauber, Simone C
|0 0000-0001-9149-3071
|b 22
700 1 _ |a Süße, Marie
|b 23
700 1 _ |a Lewerenz, Jan
|0 0000-0002-9272-529X
|b 24
700 1 _ |a Madlener, Marie
|0 0000-0002-6299-8238
|b 25
700 1 _ |a Rostasy, Kevin
|0 0000-0002-2180-5321
|b 26
700 1 _ |a Prüss, Harald
|0 P:(DE-2719)2810931
|b 27
700 1 _ |a Sühs, Kurt-Wolfram
|0 0000-0002-8077-481X
|b 28
700 1 _ |a Kümpfel, Tania
|0 0000-0001-7509-5268
|b 29
700 1 _ |a Thaler, Franziska S
|0 0000-0001-6548-0410
|b 30
700 1 _ |a Leypoldt, Frank
|0 0000-0002-8972-515X
|b 31
700 1 _ |a Geis, Christian
|0 0000-0002-9859-581X
|b 32
700 1 _ |a group, GENERATE study
|b 33
|e Collaboration Author
773 _ _ |a 10.1212/NXI.0000000000200555
|g Vol. 13, no. 3, p. e200555
|0 PERI:(DE-600)2767740-0
|n 3
|p e200555
|t Neurology: Neuroimmunology & Neuroinflammation ; official journal of the American Academy of Neurology
|v 13
|y 2026
|x 2332-7812
856 4 _ |u https://pub.dzne.de/record/285252/files/DZNE-2026-00194.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/285252/files/DZNE-2026-00194.pdf?subformat=pdfa
|x pdfa
|y Restricted
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)9001490
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 27
|6 P:(DE-2719)2810931
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEUROL-NEUROIMMUNOL : 2022
|d 2025-11-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-11-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-11-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2025-11-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-02-13T18:57:06Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-02-13T18:57:06Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2021-02-13T18:57:06Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-11-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-11-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-11-06
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-11-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-11-06
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b NEUROL-NEUROIMMUNOL : 2022
|d 2025-11-06
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2025-11-06
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2025-11-06
920 1 _ |0 I:(DE-2719)1810003
|k AG Prüß
|l Autoimmune Encephalopathies
|x 0
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)1810003
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21